Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Brentuximab vedotin.
[hodgkin lymphoma, classical]
Brentuximab
vedotin
is
an
anti-
CD
30
antibody-drug
conjugate
with
proven
efficacy
in
patients
with
CD
30
(
+
)
malignancies
,
including
classical
Hodgkin
lymphoma
and
anaplastic
large
cell
lymphoma
.
Promising
activity
has
also
been
seen
in
other
lymphomas
that
express
CD
30
.
Because
of
its
acceptable
toxicity
profile
and
significant
clinical
efficacy
,
single
-
agent
brentuximab
vedotin
is
an
approved
treatment
for
relapsed
patients
with
these
diseases
.
Brentuximab
vedotin
has
safely
been
combined
with
chemotherapy
and
is
now
being
compared
with
standard
treatments
in
randomized
trials
.